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Investigational Drugs and the Law
George F. Archambault*
T HE SUBJECT OF investigational drugs is one of the most talked about
issues of this day in law, medicine, pharmacy, the drug industry
and hospital worlds. To illustrate this point one need only look at the
headlines in the press. For example:
MEDICARE RESEARCH ON HUMANS IS SPARKING BEHIND
THE SCENES ROW OVER ETHICAL CODE.1
William Carley2 stated in the Wall Street Journal, "At the convention,
the AMA may adopt the Declaration of Helsinki, a set of general ethical
principles created by an international medical group in 1964. It leaves
doctors wide areas of discretion in matters of ethics in research with
humans." 3 Carley went on to state, ". . . whether the Helsinki principles
are adopted or rejected by AMA, a subsequent drive for the adoption of
another and controversial set of guidelines seems probable. This set,
which isn't scheduled for consideration at the AMA convention this
week, is a 14-page document written by AMA lawyers and is far more
specific and detailed than the one page Helsinki Declaration."
Also, Dr. Henry Beecher's article that appeared in the New England
Journal of Medicine4 created news in many of the leading newspapers.
Among other points the press reported were: "Beecher's statement listed
22 projects involving what he termed questionable practices," and "Medi-
cal testing without consent involves 1000 humans, doctor says." 5
American Druggist carried a news item, "Clinical investigators are
now being sued." 0 The article stated in part, ". . . several suits already
have been filed against drug investigators by persons allegedly harmed by
experimental drugs, a Cleveland attorney7 told a recent meeting of the
Drug Chemical and Allied Trade Association."
In June last year some 100 attorneys representing hospitals met for
the American Hospital Association's Annual Institute on Hospital Law.
* Dean of the College of Pharmacy, University of Florida, formerly Pharmacy
Liaison Officer, Office of the Surgeon General, U. S. Public Health Service, Wash-
ington, D. C. [This is a paper presented at the 1966 Annual Meeting of the American
College of Legal Medicine.]
1 Wall Street Journal, p. 5 (June 24, 1966).
2 Carley is the same Writer who handled the January 21, 1966, article on the lung
cancer cell study patient consent controversy involving the Jewish Chronic Disease
Hospital and the Sloan Kettering Institute.
3 Supra n. 1.
4 274 New Engl. J. of Med. (24) 1354 (June 16, 1966).
5 Washington Post, p. A2 (June 17, 1966).
6 April 12, 1965.
7 R. Crawford Morris, of Arter, Hadden, Wykoff and Van Duzer.
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Two days were spent in workshops studying new case law and statutes.
Titles VI, XVIII, and XIX of the 1965 S. S. Amendments; H. R. 2, and
the Darling case8 were key topics as were medication error law suits,
adverse drug reaction suits, and the "law" of investigational drugs.
At the Drug Information Association meeting recently 9 many M.D.'s,
directors of research for pharmaceutical firms, conducting tests at
prisons, mental institutions, and hospitals, spoke on the consent issue and
on "proper control" for drug investigational studies.
Moving directly to the subject "Investigational Drugs and the Law"
and being concerned primarily with preventative law, a topic not unlike
preventative medicine, what is it that must be known as a lawyer in
this specialty field in order to aid physicians and pharmacists involved
in clinical research, in clinical pharmacology research, in hospital ad-
ministration, and in nursing and pharmacy practices to keep them from
legal pitfalls? It is necessary to tackle the subject in a two-pronged
manner: (1) the federal and state statutes, and (2) case law.
Federal and State Statutes
As we are mainly concerned with the Food and Drug Act, a short
historical resume might well be in order before examining the statutes.
Around 1900, several children were killed in the St. Louis area as a re-
sult of the administration of a diphtheria anti-toxin produced from the
serum of a horse ill with tetanus. The result was a federal law creating
what is today the Division of Biologics Standards of the U. S. Public
Health Service. For some 34 years now this nation has had a splendid
record of safety in this area of drugs. Only one failure in the search
for a polio vaccine: the standards were not as they should have been
and the tragic Cutter polio cases resulted. You will recall these cases
were settled in the framework, not of tort negligence, but contract law,
the law of sales, on the ground of an implied warranty of fitness for use
as applied to items "inherently dangerous."
About 1910, a Federal Food and Drug Act, pushed for by the
women of the country through Good Housekeeping, came into being.
Two decades later the Elixir of Sulfanilamide tragedy occurred. A drug
firm used as a sulfanilamide vehicle the solvent diethylene glycol, not
poisonous in 1 or 2 ml. doses but lethal in large doses. The result
was that the FDA laws and regulations were again tightened, this time
to require "safety" of the product. Even then there was no strong re-
quirement as to the efficacy of the medication. A few years ago the
thalidomide disaster and the phocomelias brought about the Harris-
s Darling v. Charleston Community Memorial Hospital, 33 Ill.2d 326, 211 N.E.2d 253,
cert. den. 383 U.S. 946 (1965).
9 Chicago, M1l., June 25, 1966.
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Kefauver FDA Amendments of 1962 requiring not only drug safety but
also efficacy for our drugs.
Incidentally, the writer has in his possession what Dr. Letourneau
calls a "collector's item," the preliminary medical brochure placed in
the hands of physicians at the time the drug thalidomide went into
clinical trials in the United States. It reads in part, "A very safe and
effective new drug prepared for the treatment of nervous tension and
insomnia as well as potentiation of analgesics."
Who among us had given thought to the teratogenic effects of
medications prior to 1962? Perhaps some as to German measles but
few as to drugs. Yet, the observant, like Flemming and his penicillin
discovery, if he had thumbed through the annual publications in the
veterinary field, would have spotted a notation around 1959-1960 that
pregnant sheep pastured during the early fall on certain meadow
ranges in Idaho gave birth to deformed lambs. Why? A plant, a species
of veratrum (veratrum californicum) carried an offending glycoside or
alkaloid and this is a drug used in eclampsia. The signs were there but
not recognized.
The net results of the work of Senator Kefauver and his committee
and others who subsequently carried on that work are good. The legiti-
mate drug industry, medicine, pharmacy, and the public will benefit
greatly because of the new legislation that requires not only proof of
safety but of efficacy as well.
Medication, today, to move in the market place must be efficacious
for the purposes intended and reasonably safe. Obviously absolute
safety can never be guaranteed.
F. D. A. and Investigation Drugs
Now, proceeding to the current FDA amendments as these relate to
investigational drugs, these regulations can be summarized as follows:
1. The labels of containers holding drugs not cleared for interstate
commerce must bear the statement "Caution-New Drug-
Limited by Federal (or U. S.) law to investigational use." Note
the language used is "investigational." The word "experimental"
is taboo, it seems, in connection with human trials.
2. Three forms of statements must be filed with FDA:
Form FD 1571-Claims for exemptions-usually by a manufac-
turer, a university, or medical doctor. Some thirteen points of in-
formation are to be supplied. Here are but two: (1) the scientific
training and experience considered appropriate to qualify the
investigators as suitable experts to investigate the safety of the
particular drug (item 8), (2) the names and a summary of the
training and experience of each investigator and the same for
the monitoring investigator (item 9).
Form FD 1572-fied by the clinical pharmacology investigator.
Some six points of information are required, including such in-
3Published by EngagedScholarship@CSU, 1967
16 CLEV-MAR. L. R. (3)
formation as the qualifications of the investigator and the gen-
eral outline of protocol study. Also, the clinical investigator cer-
tifies that he will inform any patients or any persons used as con-
trols, or their representatives, that the drugs are being used for
investigational purposes and will obtain the consent of the sub-
jects, or their representatives, except when this is not feasible
or, in the investigator's professional judgment, is contrary to the
best interest of the subjects.
Form FD 1573-(a somewhat similar form to 1572) must be
filed by the clinical (not pharmacological) investigators. Four
points of information are requested, with some twelve subhead-
ings. Items such as (1) the "consent statement" previously men-
tioned, (2) the investigator agrees to report to the sponsor, (3)
the sponsor agrees to report to the FDA, at least once a year,
and (4) any adverse reaction will be promptly reported. All
records to be kept for two years and the drugs will be ad-
ministered only to subjects under the personal supervision of
other (state names) investigators responsible to him and that
the drug will not be supplied to any other investigator (fellow
physician) or to clinics for administration to a subject.
State Regulations
A state may tighten a federal law by state statute or code; however
a state does not have the power to loosen a federal code. Therefore
lawyers know that the statutes of a state and political subdivisions
thereof, such as cities, must be checked on this point of clinical investi-
gations, or more precisely, the issue here, patient consent. New York
City has special regulations on this point and probably Georgia does also
as a result of the Milledgeville Mental Institution probe of several years
ago.
The role of the New York Board of Regents is still another type of
state jurisdiction that must be analyzed. The board of fifteen Regents, in
a unanimous decision, ruled that the two doctors from Sloan Kettering
who conducted the cancer cell studies at the Jewish Chronic Disease
Hospital, had their medical licenses suspended (but stayed execution
of the sentence, placing the physicians on probation for one year) for
fraud and deceit in the practice of medicine. They were charged with
not informing the patients of the true nature of the study and for not
obtaining the voluntary consent of the fully informed patient. Adminis-
trative rulings on professional activities by such boards do carry, in
effect, the force of law.
So much for a brief review of state statutes, codes, regulations,
and jurisdiction, except to add the comment that Boards of Registration
in Medicine and Pharmacy may well find themselves policing this area
of human drug testing more actively than ever before in the last third
of this twentieth century because of the potency of new drugs and
devices.
Sept., 1967
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Now to the practical application of present day regulations. Law-
yers would be wise to inform their medical and pharmaceutical colleagues
involved in Phase II (pharmacological testing), and Phase III (clinical
testing) as to the following:
1. They should be guided by the drug firm's medical research di-
rector. He knows the law and will protect his company and the
investigator.
2. If one is in a study under Phase III (clinical testing) and re-
porting to a principal investigator, one needs to know the princi-
pal investigator's reputation for quality controls. If other of his
investigators (physicians) submit "graphite" reports on dead or
long ago released patients, your physician client could be
smirched should the names of all clinical investigators operating
with the principal investigator be released.
3. Many drug firms, since the Boston expos6, have tightened up
their quality controls on drug testing. Most drug firms can
quickly spot situations where more patient reports are submitted
than is possible with the number of doses distributed when used
in accordance with the FDA filed protocol of study.
4. For the investigator's protection, he should obtain the written
consent'0 from the fully informed patient or explain on the
patient's chart, at the time of the decision, why he did not elect
to obtain the consent.
5. Concerning the consent issue-good causes for not disclosing to
the patient that an investigational drug is being used might well
be because: (a) the patient is an unconscious child and has no
relatives, (b) the same, for an insane patient, (c) the patient
is terminal.
6. Some researchers and hospitals have added a new document for
additional protection, for want of a better name, the "Review
Statement of Patient Consent." This document goes to a peer
committee. If the committee is not satisfied with the informa-
tion furnished to the patient, as related by the patient on the
form, the investigator is asked to return to the patient and ex-
plain further the study.
7. Remember, "consent" is a matter of medical judgment. The Food
and Drug Administration does not require the consent to be in
writing," and does not require consent where the professional
judgment of the physician so indicates.
8. How does one handle the consent issue when double blind
studies are used? Inasmuch as the patient might not receive the
investigational drug but might receive the placebo, one can
state ". . . we are asking you to participate in a course of treat-
ment in which you may receive an investigational drug, or you
may be one of the control patients" and then explain the study.
This is an honest approach to the consent issue.
10 The AMA Medicolegal Forms with Legal Analysis Brochure has as Form Num-
ber 29 "Authorization for Treatment with Drug Under Clinical Investigation" (1961).
11 The Federal Register, vol. 21, no. 168, carries the new regulation of the FDA re-
quiring written consent except in certain instances (Aug. 30, 1966).
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9. The AMA law department, not the FDA, first suggested that a
consent form be used.
10. Finally, do not forget the Nuremburg trials involving medical
experimentation. Fifteen defendants were found guilty, seven
were hanged and four of the seven were physicians. 12
A discussion of investigational drugs would be incomplete if the
Five Point Statement of Principles on the Use of Investigational Drugs
in Hospitals, as approved by the Board of Trustees of the American
Hospital Association and the American Society of Hospital Pharma-
cologists (1957), was not reviewed at this point. These elements are:
1. Investigational drugs should be used only under the direct super-
vision of the principal investigator, who should be a member of
the medical staff and who should assume the burden of securing
the necessary consent.
2. The hospital should do all in its power to foster research con-
sistent with adequate safeguard for the patient.
3. When nurses are called upon to administer investigational drugs,
they should have available to them basic information concerning
such drugs; dosage forms, strengths available, actions and uses,
side effects, and symptoms of toxicity, and so forth.
4. The hospital should establish, preferably through the pharmacy
and drugs therapeutics committee, a central unit where essential
information on investigational drugs is maintained and whence
it may be made available to authorized personnel.
5. The pharmacy department is the appropriate area for the storage
of investigational drugs, as it is for all other drugs. This will also
provide for the proper labeling and dispensing in accord with the
investigator's written orders.
Tort Negligence
At this point tort negligence law should be considered. Attorneys
should advise their colleagues to:
1. Insist that the investigator and hospital officials make certain
that the code used in double blind and other studies be capable
of being broken at the hospital should a patient's life or health
become jeopardized. 13
2. Not permit a sponsor or chief investigator to interfere with
legal responsibility as to "code breaking" as some may do to
"protect the integrity of the research."
Parke Davis of Detroit has an excellent system for breaking the code
when a patient's condition so warrants. The system was developed by
Dr. Wheeler of Parke Davis' Research Division-a sealed envelope is
used in which is placed an 8% x 11 punch card, not unlike a "chance
card." A typical case study might have the following caption:
12 See, Hospital Management, "A Drug Moves Into Human Trials" (April 1963).
13 See Editorial, "Hospitals" 32 J. Amer. Hospital Assoc. 35 (Jan. 1, 1958).
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Group A-Drug A-10 mgm.
Group B-Drug A-25 mgm.
Group C-Drug B-50 mgm.
Group D-Drug B-150 mgm.
Group E-Placebo
The doctor knows he is using drugs A and B, each in two strengths,
and a placebo. The card controls fifty patients. If "Patient No. 12" is
in trouble, the M.D. pulls slot 12 on the card and may see "D," meaning
the patient is on "B" drug with a 150 mgm. dose. The rest of the study
is not imperiled as the investigator has the answer to the one case
he has concern for. The card must be returned to Parke Davis at the
end of the study in the same sealed envelope.
The following common law cases: Darling v. Charleston Community
Hospital,14 Sullivan v. Sister of St. Francis,15 and Norton v. Argonaut
Insurance Co.,' 6 on careful reading lead to these inescapable conclusions:
1. Hospitals, more and more, are being held liable for misfeasance
and nonfeasance of employees.
2. Hospital administrators find themselves personally involved in
not only malpractice tort litigation but also criminal negligence
cases.
3. Statement of Principles, such as that on the Use of Investiga-
tional Drugs in Hospitals by the Board of Trustees of the Ameri-
can Hospital Association, plus the Joint Commission and Medi-
care Standards, are being increasingly used as "tools" by plain-
tiff attorneys to help prove alleged negligence.
4. Attorneys need to advise their medical colleagues to set up
systems to periodically check the workers under their super-
vision, to make certain that subordinates (M.D.'s and others)
are following the laws, rules, regulations, policies, and pro-
cedures set up for patient safety. Otherwise, the client may
find himself trying to defend a most difficult legal position.
5. And last, but not least, the client and his institution should be
covered with adequate malpractice insurance covering investi-
gational drug study activities.
14 Supra n. 8.
15 374 S.W.2d 294 (Tex. Civ. App. 1963).
16 144 So.2d 249 (La., 1962).
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